TrialPloS one2022

Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial.

Chang Ki Yoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.